Rock SpringsCapital
Investments,News,Biotech / MedTech,Singapore
MiRXES secures $77M Series C funding to accelerate multi-cancer early detection pipeline
Singapore-based biotechnology company MiRXES announced on Thursday it has raised $77 million in Series C funding to accelerate its push to deliver cancer early detection tests and…
July 8, 2021